Catherine Creticos
YOU?
Author Swipe
View article: Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study
Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study Open
Background Lenacapavir is a twice-yearly HIV-1 capsid inhibitor approved, in combination with other antiretrovirals, for the treatment of heavily treatment-experienced people with multidrug-resistant HIV, based on the Phase 2/3 CAPELLA stu…
View article: P-1378. Linezolid For Early Syphilis Treatment: Pilot study
P-1378. Linezolid For Early Syphilis Treatment: Pilot study Open
Background Syphilis rates have been increasing. At the same time, important shortages of benzathine penicillin G have been reported. Existing alternatives, doxycycline, tetracycline, and azithromycin are inadequate to treat syphilis in all…
View article: 155. Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study
155. Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study Open
Background Lenacapavir (LEN) is a highly potent, long-acting HIV-1 capsid inhibitor approved in combination with other antiretrovirals (ARVs), for the treatment of heavily treatment-experienced (HTE) people with HIV-1 (PWH) with multidrug …
View article: Dual Antiretroviral Regimens for HIV – Here to Stay
Dual Antiretroviral Regimens for HIV – Here to Stay Open
It has been twenty-five years since antiretroviral therapy (ART) for human immunodeficiency virus (HIV) became available. Treatment has evolved substantially over these decades to become highly effective and produce substantial improvement…
View article: Cryptococcal Meningitis in an Immunocompetent Patient with a Ventriculo-Pleural Shunt
Cryptococcal Meningitis in an Immunocompetent Patient with a Ventriculo-Pleural Shunt Open
Cryptococcal meningitis is the most common form of infection caused by Cryptococcus yeast species, followed by pulmonary infection. It is an opportunistic infection seen in patients with impaired cell immunity, most frequently in HIV patie…
View article: 1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial
1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial Open
Background In the DISCOVER PrEP trial, emtricitabine/tenofovir alafenamide (F/TAF) was noninferior to emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV prevention. Here we report the bone safety outcomes of F/TAF and F/TDF. Metho…
View article: 661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)
661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311) Open
Background Ibalizumab (IBA), a humanized monoclonal antibody, is the first CD4-directed post-attachment HIV-1 inhibitor. It was approved by the FDA in March 2018 based on results from the pivotal Phase 3 TMB-301 clinical study. The TMB-311…
View article: Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results
Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results Open
Background Boosted protease inhibitor regimens (bPIs) are effective and often used in HIV-infected individuals with difficulties with adherence, but they can have drug–drug interactions and GI adverse effects. Bictegravir (B), a novel, pot…